ACAT
Acasia Technology, Inc.10.00
+0.00+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
42.96MP/E (TTM)
-Basic EPS (TTM)
-0.02Dividend Yield
0%Recent Filings
10-K
FY2023 results
NP Life Sciences Health Industry Group Inc. posted FY2023 revenue of $164,621, up 61% from $102,002 in 2022, driven by $99,599 from its new GW Health subsidiary's career consulting services, while classical Chinese studies consulting added $65,022. Yet expenses climbed 37% to $165,311, mainly from higher professional fees, yielding a slim net loss of $2,935 versus $18,856 last year. Q4 momentum stayed modest, with no quarterly breakdowns disclosed but overall growth signaling early traction in health consulting amid stagnant core education ops. Cash dipped to $70,614 after a $22,362 shareholder loan at 4% interest, supporting liquidity without capex or buybacks. No annual guidance issued. Regulatory hurdles in cross-border education tours pose risks to quarterly progress.
10-Q
Q3 FY2023 results
NP Life Sciences Health Industry Group swung to a nine-month net profit of $12,420 through September 30, 2023, up from a $35,454 loss a year earlier, fueled by revenue jumping 176% y/y to $154,614 on $99,599 from new subsidiary GW's consulting services—yet Q3 revenue dipped 57% q/q to $17,515, posting a $37,670 loss as general and administrative expenses rose 31% y/y to $119,442 on higher professional fees. Operating profit hit $35,172, but taxes of $22,333 on GW's $52,509 earnings trimmed the bottom line; no material operating vs. net delta beyond that. Cash drained to $84,551 after $59,670 in operating outflows, offset by a $22,362 related-party loan due April 2024 at 4% with no collateral. Subsidiaries in Hong Kong and Singapore added no activity. Weak internal controls persist as a key risk.
10-Q
Q2 FY2023 results
NP Life Sciences Health Industry Group swung to profitability in Q2 FY2023 ended June 30, 2023, with revenue surging 815% year-over-year to $137,099 for the six months, driven by $99,599 from its new GW Health subsidiary's consulting services, while Q2 alone hit $107,099 (derived). Operating profit climbed to $72,617 YTD from a $30,015 loss last year, yielding a 53.0% margin after $64,482 in administrative expenses up 43% on professional fees; net income reached $47,795 after $24,628 taxes, with EPS at $0.00 due to rounding on 42,959,574 shares. Cash edged up to $125,111, bolstered by a $22,362 related-party loan at 4% due April 2024, though operating cash used $19,110. No free cash flow disclosed in the 10-Q. The pivot to health consulting fueled momentum, yet going concern doubts linger from accumulated deficits.
10-Q
Q1 FY2023 results
NP Life Sciences Health Industry Group notched its first revenue of $30,000 in Q1 2023, up from zero a year earlier, flipping to an operating profit of $1,225 while trimming general and administrative expenses 7.4% year-over-year to $28,775 (derived). This modest gain, driven by promotion and consulting services for international study tours, lifted net income to $1,222—versus a $31,092 loss last year—with diluted EPS holding at $0.00 on 42,959,574 shares, showing no anti-dilution effects. Cash climbed to $140,078, bolstered by $18,219 in operating cash flow, yet customer advances of $112,646 signal reliance on three key clients. No debt burdens the balance sheet. Small steps forward, but going concern doubts linger.
10-K
FY2022 results
NP Life Sciences Health Industry Group Inc. posted FY2022 revenue of $102,002, up 191% y/y from $34,992, driven by expanded consulting services on classical Chinese studies, though its new mental health subsidiary GW generated no revenue yet. The narrower net loss of $18,856 marked improvement from $65,677 in 2021, with operating expenses rising 20% to $120,857 amid higher professional fees, but cash from operations flipped to a $93,873 inflow, boosting year-end cash to $121,859. Q4 momentum showed promise through $99,599 in customer advances for future GW services, signaling quarterly acceleration in bookings. Liquidity remains tight with no debt, relying on equity raises for growth. Yet, heavy dependence on two customers poses risks to quarterly revenue stability.
AACG
ATA Creativity Global
0.91+0.03
AMBO
Ambow Education Holding Ltd. Am
3.65+0.04
ASPU
Aspen Group Inc.
0.21+0.06
GOTU
Gaotu Techedu Inc.
2.39+0.01
KIDZ
Classover Holdings, Inc.
0.28+0.02
MYND
Mynd.ai, Inc.
0.55-0.02
SKIL
Skillsoft Corp.
6.61+0.94
TSPH
CreateAI Holdings Inc.
0.14-0.02
VSA
VisionSys AI Inc.
0.10-0.01
YQ
17 Education & Technology Group
3.73-0.10